[go: up one dir, main page]

IL160605A0 - Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity - Google Patents

Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity

Info

Publication number
IL160605A0
IL160605A0 IL16060502A IL16060502A IL160605A0 IL 160605 A0 IL160605 A0 IL 160605A0 IL 16060502 A IL16060502 A IL 16060502A IL 16060502 A IL16060502 A IL 16060502A IL 160605 A0 IL160605 A0 IL 160605A0
Authority
IL
Israel
Prior art keywords
prophylaxis
obesity
systems
treatment
preparing medicaments
Prior art date
Application number
IL16060502A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL160605A0 publication Critical patent/IL160605A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL16060502A 2001-08-31 2002-08-17 Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity IL160605A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10142666A DE10142666A1 (de) 2001-08-31 2001-08-31 Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
PCT/EP2002/009205 WO2003020263A1 (de) 2001-08-31 2002-08-17 Verwendung von c2-substituierten indan-1-ol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas

Publications (1)

Publication Number Publication Date
IL160605A0 true IL160605A0 (en) 2004-07-25

Family

ID=7697236

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16060502A IL160605A0 (en) 2001-08-31 2002-08-17 Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
IL160605A IL160605A (en) 2001-08-31 2004-02-26 Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160605A IL160605A (en) 2001-08-31 2004-02-26 Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity

Country Status (13)

Country Link
US (2) US20030134879A1 (xx)
EP (1) EP1425007B1 (xx)
JP (1) JP2005503397A (xx)
AT (1) ATE308321T1 (xx)
AU (1) AU2002336984B2 (xx)
CA (1) CA2458526A1 (xx)
DE (2) DE10142666A1 (xx)
DK (1) DK1425007T3 (xx)
ES (1) ES2250710T3 (xx)
IL (2) IL160605A0 (xx)
MX (1) MXPA04001852A (xx)
PE (1) PE20030335A1 (xx)
WO (1) WO2003020263A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
EP2389171B1 (en) * 2009-01-26 2016-03-30 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
CN113660932B (zh) * 2019-03-29 2024-07-12 景凯生物科技股份有限公司 具有侧链烷基与烯基延伸的苯基衍生物及包括有其的药学组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2345146A1 (fr) * 1976-03-23 1977-10-21 Logeais Labor Jacques Nouveau medicament a base d'(hydroxy-2 indanyl-2) 1-propanol
EP0009554B1 (de) * 1978-07-27 1983-04-27 Schering Aktiengesellschaft Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
JPH01503777A (ja) * 1985-10-04 1989-12-21 マツジヨ‐ニ‐ウインスロツプ・ソチエタ・ペル・アチオニ 縮合脂環式アミノアルコール類
MX13484A (es) 1987-10-19 1993-05-01 Pfizer Procedimiento para la obtencion de tetralinas, cromanos y compuestos relacionados, sustituidos
EP0874800B1 (en) * 1995-12-06 2003-08-06 Venantius Limited Indane dimer compounds with smooth muscle relaxing and/or mast cell stabilising and/or antiinflammatory activity
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
DE10142660A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142662B4 (de) * 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142667B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US7763662B2 (en) 2010-07-27
ATE308321T1 (de) 2005-11-15
IL160605A (en) 2010-12-30
JP2005503397A (ja) 2005-02-03
PE20030335A1 (es) 2003-05-20
DE50204801D1 (de) 2005-12-08
CA2458526A1 (en) 2003-03-13
US20050080057A1 (en) 2005-04-14
DK1425007T3 (da) 2006-03-13
WO2003020263A1 (de) 2003-03-13
ES2250710T3 (es) 2006-04-16
MXPA04001852A (es) 2004-06-15
AU2002336984B2 (en) 2006-10-26
EP1425007A1 (de) 2004-06-09
EP1425007B1 (de) 2005-11-02
DE10142666A1 (de) 2003-03-20
US20030134879A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
AU2003296993A8 (en) Cyclopropyl compounds as ccr5 antagonists
AU2003297048A8 (en) Cyclohexyl compounds as ccr5 antagonists
HK1057752A1 (en) N-phenyl-2-pyrimidine-amine derivatives
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
MY132789A (en) Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
NO20052739L (no) CCR5-antagonister som medikamenter
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
GB0112348D0 (en) Compounds
DE60205455D1 (de) Naphthyridinderivate
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
MXPA04001847A (es) Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad.
HK1044467A1 (en) Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
IL160605A0 (en) Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
IL160601A0 (en) Use of derivatives of c2-substituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
MXPA04001853A (es) Uso de sistemas de indan-1-ona c2-substituida para producir medicamentos para la profilaxis o tratamiento de obesidad.
IL160603A0 (en) C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals
IL160604A0 (en) C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals